Morphogenesis, Inc.

16 articles about Morphogenesis, Inc.

• Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a Business Overview

  12/14/2023

  Morphogenesis, Inc., a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, announced its corporate rebranding and provided a business overview.

• Morphogenesis, Inc. Biomarker Analysis Data from IFx-Hu2.0 in Melanoma Refractory to Anti-PD1-Based Therapies Demonstrates Ability to Overcome Primary Resistance to Checkpoint Inhibitors and Trigger an Innate Immune Response

  11/8/2023

  Morphogenesis, Inc. announced positive biomarker analysis data from its first-in-human study evaluating IFx-Hu2.0 for patients with melanoma refractory to anti-PD1-based therapies.

• Morphogenesis, Inc to Present at the Virtual Investor Summer Spotlight Series

  7/6/2023

  Morphogenesis, Inc. announced that Dr. James Bianco, Chief Executive Officer of Morphogenesis will present at the Virtual Investor Summer Spotlight Series on Tuesday, July 11, 2023 at 3:00 PM ET.

• Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0

  6/5/2023

  Morphogenesis, Inc. and CohBar, Inc. (CWBR) ("CohBar"), today announced positive initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs.

• Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced MCC and Cutaneous Squamous Cell Carcinoma (cSCC)

  6/5/2023

  Morphogenesis, Inc. and CohBar, Inc., announced positive initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs.

• Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - May 30, 2023

  5/30/2023

  Morphogenesis, Inc. and CohBar, Inc. today announced that Morphogenesis' abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

• Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/30/2023

  Morphogenesis, Inc. (“Morphogenesis”) and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.

• CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

  5/23/2023

  CohBar, Inc. and Morphogenesis, Inc. today announced that they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.

• Morphogenesis Inc. Acquires TυHURA Biopharma’s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy

  3/28/2023

  Morphogenesis Inc., a Phase 3 clinical stage biopharmaceutical company developing novel personalized cancer vaccines, announced today that it has entered into a definitive asset purchase agreement, in a stock for stock transaction, to acquire TυHURA’s novel ADCs targeting MDSCs to modulate tumor microenvironment immunosuppression.

• 

  Preview: Life Science Women’s Conference

  2/12/2020

  The Life Science Women’s Conference is being held on February 19 and 20 at the Tampa Bay Convention Center in Tampa, Florida. Co-founded by Patti Rossman and Steve Fiske, the conference is an opportunity for women to accelerate their life science careers via mentoring, networking and education.

• University of Florida And Tampa-Based Morphogenesis, Inc. Developing Innovative Device For Capturing Rare Cells

  2/4/2015

• Morphogenesis, Inc. Announces USDA-Sanctioned Clinical Trial For Promising Equine Cancer Vaccine

  9/9/2014

• Morphogenesis, Inc. Chooses Florida Veterinary Referral Center As Newest Licensee For Its Immunefx™ Cancer Vaccine

  8/11/2014

• Cancer Breakthrough Team At Morphogenesis, Inc. Announces New Worldwide Cancer Vaccine Update

  6/2/2014

• Morphogenesis, Inc. Signs Cancer Treatment Deal with Novartis Animal Health Inc.

  3/24/2010

• Morphogenesis, Inc. Signs Agreement With Novartis Corporation to Further the Development of Cancer Immunotherapy for Companion Animals

  3/24/2010